Primary aldosteronism management depends on a multitude of factors, and surgical adrenalectomy is generally recommended in ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...

Detailed price information for Cspc Pharmaceuticals Group Ltd (CHJTF) from The Globe and Mail including charting and trades.

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million.

It doesn’t take a rocket ― er, dick scientist ― to know that it’s not just whiskey that causes whiskey dick. Vodka drinkers ...

The epidemiology of hypertension in India has undergone a malignant shift, moving from a disease of the elderly to a ...

Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of ...

An announcement from Mineralys Therapeutics, Inc. ( ($MLYS) ) is now available. On January 6, 2026, Mineralys Therapeutics provided a corporate ...

Adrenal glands produce hormones that affect heart rate, blood pressure, and stress response. High cortisol levels can cause ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of [68Ga]Ga-PentixaFor in treatment-resistant hypertension and Primary AldosteronismT ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...